Meropenem Aptapharma

Meropenem, the active ingredient in Meropenem Aptapharma, is a carbapenem antibiotic presented as an injection for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia, meningitis, and severe sepsis in hospitalized patients.

GNH USA supplies Meropenem Aptapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a carbapenem antibiotic used to treat serious bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: provides broad‑spectrum bactericidal activity to resolve infection. - Complicated urinary tract infections: eliminates resistant uropathogens and restores urinary health. - Nosocomial pneumonia: targets hospital‑acquired lung pathogens for rapid clinical improvement. - Meningitis: penetrates the cerebrospinal fluid to eradicate causative bacteria. - Severe sepsis: offers rapid bacterial clearance in critically ill patients.

Adverse reactions may occur with any intravenous antibiotic and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: localized skin erythema or pruritus. - Elevated liver enzymes: transient increase in transaminases. - Headache: mild, often resolves without intervention. - Infusion site reactions: pain or phlebitis at the injection site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile colitis: severe diarrhea requiring medical attention. - Anaphylaxis: acute hypersensitivity with respiratory or cardiovascular compromise. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: acute kidney injury in susceptible individuals. - Hypersensitivity reactions: including Stevens‑Johnson syndrome.

Careful assessment and monitoring are required before and during treatment with Meropenem. - Renal function: adjust dose in patients with impaired kidney function. - Allergy: avoid in individuals with known carbapenem or β‑lactam hypersensitivity. - Seizure risk: monitor patients with a history of epilepsy or CNS disorders. - Pregnancy and lactation: use only if potential benefits justify potential risks. - Drug interactions: review concomitant medications for possible interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with several co‑administered drugs; awareness of interaction severity helps guide clinical decisions.

Major Interactions (Avoid): - Valproic acid: may increase serum levels leading to toxicity. - Cisplatin: additive nephrotoxicity risk. - Probenecid: can reduce renal clearance of Meropenem.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes. - Aminoglycosides: watch for combined nephrotoxic effects. - Warfarin: monitor INR for potential anticoagulation changes.